|
A co-founder of the Avicena Group, Dr. Kaddurah-Daouk has contributed significantly to the field of energy impairment in disease through her work on the creatine kinase system. With training at Johns Hopkins, Massachusetts General Hospital - Harvard Medical School, and the Massachusetts Institute of Technology, she is credited with several breakthrough inventions that are protected by a portfolio of more than 60 patents and patent applications. A number of these patents are recognized as the industry's earliest patent filings around creatine kinase and energy impairment and neurodegenerative diseases, as well as metabolomics.
Currently, Dr. Kaddurah-Daouk serves as the president of the Metabolomics Society; is an adjunct associate professor at Duke University Medical Center and maintains a research affiliation with the Dana Farber Cancer Institute. In addition to co-founding the Avicena Group, she is also credited as a co-founder of Metabolon, another leading biotechnology company.
Dr. Kaddurah-Daouk has key scientific publications in the field of energy impairment in disease. Her collaboration with Dr. M. Flint Beal and others at Harvard Medical School resulted in scientific discoveries that confirmed both the important role of creatine kinase in neuronal cell death and the beneficial effect of creatine supplementation for the potential treatment of ALS and other neurodegenerative diseases.
Dr. Kaddurah-Daouk received a Ph.D. in biochemistry from the American University in Beirut and completed a post-doctoral fellowship at the Johns Hopkins Medical School where she worked for two years with Nobel Laureate Dr. Hamilton Smith on the mechanism of protein-DNA recognition. | 